Author

E. Farmaki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. H. Bild· 1 shared A. Nath· 1 shared K. L. Karimi· 1 shared P. A. Cosgrove· 1 shared R. Emond· 1 shared V. K. Grolmusz· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. H. Bild

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer

E. Farmaki, A. Nath, R. Emond, K. L. Karimi, V. K. Grolmusz, P. A. Cosgrove, A. H. Bild

This study shows that combining ONC201/TIC10 with everolimus improves therapeutic response in metastatic ER+ breast cancer by targeting mitochondrial function and oxidative phosphorylation.

eLife · Sep 29, 2023Peer-reviewedCancer Biology